A Phase II Trial Investigating Vemurafenib for the Treatment of Hairy Cell Leukemia

Video

Jae Park, MD, attending physician, Leukemia Service, Memorial Sloan-Kettering Cancer Center, describes the design of a trial analyzing vemurafenib for the treatment of patients with hairy cell leukemia.

Clinical Pearls

Jae Park, MD, attending physician, Leukemia Service, Memorial Sloan-Kettering Cancer Center, describes the design of a trial analyzing vemurafenib for the treatment of patients with hairy cell leukemia.

  • This phase II trial has 13 patients enrolled and is still accruing
  • Patients in the trial will receive the same dose of vemurafenib that is approved for the treatment of late-stage melanoma
  • Following three cycles of therapy, disease response is assessed, and patients can continue on vemurafenib for three additional cycles
Related Videos
Gary J. Schiller, MD, an expert on MDS
Gary J. Schiller, MD, an expert on MDS
Jamie Koprivnikar, MD, and Hana Safah, MD, experts on MDS
Related Content